AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04283162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Dobesilate
Description: use calcium dobesilate at the dosage of 500 mg, orally, 3 times per day, for 12 months
Study NCT04283162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: maintain lifestyle habits and the usual treatment
Study NCT04283162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: maintain lifestyle habits and the usual treatment
Study NCT03287167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 month DAPT
Description: Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on monotherapy with ASA only, unless contraindications for ASA emerge.
Study NCT03287167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 months DAPT
Description: Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 6 months, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
Study NCT01837992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Study NCT02311413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
Study NCT03810170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: safe sex and HIV/STD prevention education via a website
Description: website providing positive psychology-based advice and education for women over the age of 50 who are divorced. embedded in site is safe sex education.
Study NCT01837992 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: delayed primaquine
Study NCT00183092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinacrine
Description: 100mg by mouth three times a day
Study NCT00183092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg by mouth three times a day
Study NCT04001881 — intervention group
Intervention type: OTHER
Intervention: Transthoracic echocardiography
Description: A standard TTE protocol is used in all patients and included the following views: subcostal 4-chamber (SUBC), apical 4-chamber (4CH), apical 2-chamber (2CH), apical 3-chamber (3CH), parasternal long (LAX) and short axis (SAX).
Study NCT04001881 — intervention group
Intervention type: DRUG
Intervention: Spinal anesthesia
Description: Spinal anesthesia is introduced with a single intrathecal injection of 12 to 18 mg (15 mg average dose) plain ropivacaine (0.75% solution) using a 22 or 25-gauge needle (pencil-point) with the patient in the lateral position.
Study NCT02052232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental protein powder sachet
Description: mixed with 8 oz. water
Study NCT02052232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control protein powder sachet
Description: mixed with 8 oz. water
Study NCT01950533 — intervention group
Intervention type: PROCEDURE
Intervention: Oral food challenge
Description: Confirmation of allergy to egg, milk and/or peanut through an oral food challenge or documentation of a positive oral food challenge.
Study NCT03810170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: written materials on safe sex
Description: 2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
Study NCT03008174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early one-way speaking valve (OWSV) assessment
Description: The OWSV assessment by speech language pathologists will be completed at 12-24 hours following percutaneous tracheostomy procedure, which is earlier than the current standard of care of 48 hours or later.
Study NCT03082144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: MTX 15 mg,via lumbar puncture,once per week, 4 weeks in total
Study NCT03082144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Ara-C 50mg,via lumbar puncture,once per week, 4 weeks in total
Study NCT03082144 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
Study NCT03082144 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
Study NCT01465022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined estrogen-progestin pill
Description: 1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo
Study NCT01465022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progestin-only pill
Description: .35 mg norethindrone once a day orally
Study NCT01327300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: Apriso is a 5-ASA drug with Intellicor ™ extended-release delivery technology. A 1.5 gram dosage of Apriso (equaling four 375 mg capsules) once a day will be administered orally for a period of 12 weeks followed by a 3 week wash out prior to crossing over to the placebo arm.
Study NCT01327300 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules (.375 gm sugar pill capsules) administered orally once a day. This group will receive the placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
Study NCT02524457 — intervention group
Intervention type: OTHER
Intervention: This is an observational study. There are no interventions
Study NCT03492099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: Patients in this study will receive dosages to be determined by a physician that are specific to each patient.
Study NCT02310464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-833/OBI-821
Study NCT04588987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1
Description: Neoadjuvant PD-1 and Apatinib for rHGG. Adjuvant PD-1 and Apatinib for rHGG
Study NCT04159233 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Behavioral Therapy for Insomnia (BBTI)
Description: Participants will receive evidence-based 'Brief Behavioral Therapy for Insomnia' (BBTI), tailored to meet the needs of former football players. BBTi is a brief, efficacious treatment that focuses on modifying behaviors, rather than cognitive domains. The treatment emphasizes education, motivational tools, and specific behavioral recommendations (e.g., restricting time in bed) and will be administered through weekly phone calls with a trained sleep interventionist over 4-weeks.
Study NCT04475133 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ultrasound guided percutaneous neuromodulation
Description: It is a technique that consists in the electrical stimulation of peripheral nerve trunks, inserting an acupuncture needle in its path and using it as an electrode to apply electrical current
Study NCT04475133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous neuromodulation
Description: It is a technique that consists in the electrical stimulation of peripheral nerve trunks, inserting an acupuncture needle in its path and using it as an electrode to apply electrical current
Study NCT02746211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Titre Influenza virus
Description: High Titre Influenza virus
Study NCT02746211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium - High Influenza virus
Description: Medium - High Influenza virus
Study NCT02746211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium Low Titre Influenza virus
Description: Medium Low Titre Influenza virus
Study NCT02746211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low titre
Description: Low titre
Study NCT01123109 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3-D Endoanal Ultrasound
Description: The subject will be placed in the supine position with their feet in the stirrups and a drape will be used, exposing only the anus and perineum in order to introduce the probe. In order to prevent and minimize any potential discomfort, the lubricated ultrasound probe will be gently inserted into the anal canal up to the anal verge, with minimal manipulation of the probe once inserted. The scan lasts approximately two minutes and the entire exam will take no more than five minutes.
Study NCT01978665 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: prednisone
Description: similar size tablets
Study NCT01978665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone
Description: similar size tablets
Study NCT00121641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT) Open Label
Study NCT00121641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, 500-2000 mg (as needed for rescue)
Study NCT00121641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Tablets, Oral, 500-2000 mg (as needed for rescue)
Study NCT02676505 — intervention group
Intervention type: BEHAVIORAL
Intervention: Coached pushing group
Description: It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds.
Study NCT02676505 — intervention group
Intervention type: BEHAVIORAL
Intervention: uncoached pushing group
Description: It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth. .
Study NCT04354207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral vein punction
Description: Vitamin D level, vitamin D receptor genetic polymorphisms, allergen specific IgE and total IgE will be measured in peripheral blood
Study NCT04354207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stool collection
Description: Gut microbiome will be investigated in stool samples.
Study NCT03302676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chewing gum
Study NCT03475992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-power microwave breast imaging system
Description: Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump
Study NCT02607436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate
Description: Sarpogrelate
Study NCT02607436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin
Study NCT02607436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin
Study NCT03380585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciprocating single-file system
Description: After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.The device in the experimental group moves in CW and CCW direction with different angles. It is a single-file endodontic file system. The intervention is reciprocating single-file system. A Reciproc single-file will be used for enlarging apical foramen. In the active comparator group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
Study NCT03380585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotational multi-file system.
Description: After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged. In this group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
Study NCT04026477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Universal Trauma-Informed Care and Cultural Humility Training
Description: Instructional video and workshop
Study NCT04026477 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlisted Universal Trauma-Informed Care and Cultural Humility Training
Description: Instructional video and workshop following waitlist period
Study NCT02695199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic varicocelectomy
Description: Traditional laparoscopic varicocelectomy assisted by laparoscopic Doppler ultrasound
Study NCT02695199 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Microscopic Subinguinal varicocelectomy
Description: Infertile patients with clinically palpable varicoceles were selected to receive microscopic Subinguinal varicocelectomy
Study NCT02003872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spatz 3 intragastric balloon
Description: Intra gastric balloon implanted using gastroscopy
Study NCT03138005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: target SpO2 98-100%
Description: Prehospital, post-ROSC oxygen maintained at ≥10L/minute of oxygen (equivalent to \~100% oxygen) into SGA/ETT if hand ventilated or 100% (i.e. FiO2 of 1.0) oxygen settings if mechanically ventilated. Patients will continue on treatment to handover in the ED. Between arrival at ED and first ABG in ICU, the oxygen setting may then be decreased provided SpO2 is maintained between 98-100%.
Study NCT03138005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: target SpO2 90-94%
Description: Prehospital, post-ROSC oxygen reduced initially to 4L/minute (i.e. approximately 70% oxygen) into SGA/ETT if hand ventilated or an air mix setting if mechanically ventilated. If oxygen saturation remains ≥94% for 5 minutes, the oxygen flow rate will be further reduced to 2L/minute (i.e. approximately 46% oxygen) and hand ventilated to target an oxygen saturation between 90-94%. This treatment will continue to patient handover in the emergency department. Between arrival at ED and first ABG in ICU, oxygen will be titrated to target a oxygen saturation of 90-94%.
Study NCT02424968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given per standard institutional practice
Study NCT02424968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT02424968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT02424968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant
Description: Undergo nonmyeloablative allogeneic HSCT
Study NCT02424968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells
Description: Receive CD8+ memory T-cells via IV
Study NCT02598921 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: three dimensional ultrasound
Study NCT02598921 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Office hysteroscopy
Study NCT01732913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally twice daily
Study NCT01732913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
Study NCT01732913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
Study NCT01732913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Idelalisib
Description: 150 mg tablets administered orally twice daily
Study NCT01732913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 mg tablets administered orally twice daily
Study NCT00697281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: Tablets twice daily for 8 days~Dose level 1
Study NCT00697281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: Tablets twice daily for 8 days~Dose level 2
Study NCT00697281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: Tablets twice daily for 8 days~Dose level 3
Study NCT00697281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: Tablets twice daily for 8 days~Dose level 4
Study NCT00697281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets twice daily for 8 days~Dose level 5
Study NCT02831322 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention was a nonsurgical technique for treating obstructive coronary artery disease
Study NCT02831322 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention was a nonsurgical technique for treating obstructive coronary artery disease
Study NCT04356482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: convalescent plasma
Description: In phase 1, different amounts of convalescent plasma will be evaluated depending on the severity of the case.~In phase 2, both clinical, laboratory, imaging and viral presence (effectiveness) and safety will be evaluated.
Study NCT01409369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4995819
Description: single oral dose
Study NCT01409369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO4995819
Description: single oral dose
Study NCT01409369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated charcoal
Description: orally 3 times daily, Days 1-7
Study NCT02904655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: healthy diet
Description: Participants were provided meals and snacks for one month that represented a healthy diet that is high in unsaturated fats, approximating a Mediterranean diet
Study NCT01146964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MSSICS
Description: Manual super small incision cataract surgery
Study NCT01146964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Description: cataract surgery with Phacoemulsification
Study NCT01171209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta and human leukocyte Interferon-α
Description: One single injection of interferon(IFN)- β and one single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c. with 1-7 days follow-up.
Study NCT02106728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Family Therapy
Description: Multi-Family Therapy is conducted once per week over the course of 8 weeks for 1.5 hours per session. Therapy is provided to a minimum of 3 families and a maximum of 6 families with the aid of two to three therapist group leaders. Group topics are set and cover material on eating disorder psychoeducation, care-giving styles, meal support, and relapse prevention.
Study NCT02106728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Family Therapy
Description: Supportive Family Therapy is treatment as usual in the eating disorders program at TGH. Families meet independently with a therapist once per week for 1 hour per session. The length of the therapy and the topics of therapy are decided upon collaboratively with the therapist and the family.
Study NCT01412203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Schools! BC
Description: AS! BC applies a socioecological, whole school approach to promote healthy living within the elementary school context. Schools are provided with the tools and support needed to create customized action plans that promote physical activity (PA) and healthy living across six Action Zones (School Environment, Scheduled Physical Education (PE), Classroom Action, Family and Community, Extra-curricular, School Spirit). Generalist teachers receive training and resources to implement their Action Plan with the ultimate goal of providing students with 150 minutes of PA/week. The model is choice-based; teachers are asked to provide 15 additional minutes of PA/day within the Classroom Action Zone. The activities require minimal equipment and can be performed in the classroom, hallway or on the school playground.
Study NCT03054857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: After skin incision, the dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.